MoonLake Immunotherapeutics
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLTX research report →
Range $35 – $50
Price Chart
About the company
MoonLake Immunotherapeutics operates as a clinical-stage biopharmaceutical company, concentrating its efforts on discovering and developing novel therapies. The company's primary focus is the advancement of Sonelokimab, an innovative, investigational Nanobody-based treatment engineered to target inflammatory conditions. Currently, Sonelokimab is undergoing mid-stage (Phase II) clinical trials for a range of inflammatory diseases, including hidradenitis suppurativa, psoriatic arthritis, and both ankylosing spondylitis and radiographic axial spondyloarthritis.
- CEO
- Jorge Santos da Silva
- IPO
- 2020
- Employees
- 130
- HQ
- Zug, ZG, CH
Get TickerSpark's AI analysis on MLTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33B
- P/E
- -4.12
- Fwd P/E
- 6.63
- PEG
- 0.13
- P/S
- 0.00
- P/B
- 2.74
- EV/EBITDA
- -3.82
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.68%
- ROIC
- -50.65%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $-2,616,000+0.0%
- Op Income
- $-244,834,000
- Net Income
- $-227,318,000-91.1%
- EPS
- $-3.53-86.8%
- OCF Growth
- -68.1%
- FCF Growth
- -67.4%
- 52W High
- $62.75
- 52W Low
- $5.95
- 50D MA
- $18.77
- 200D MA
- $16.66
- Beta
- 1.07
- RSI (14)
- 37
- Avg Volume
- 1.22M
No earnings-call transcripts are available for MLTX yet.
- Free Float
- 86.7%
- Shares Outstanding
- 84.12M
- Float Shares
- 72.92M
of shares held by institutions
159 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Bvf Inc/Il | 16.00M | 0 |
| Deep Track Capital, LP | 7.00M | ▲ 590.16K |
| T. Rowe Price Investment Management, Inc. | 4.28M | ▲ 4.28M |
| Janus Henderson Group PLC | 3.45M | ▲ 1.36M |
| D. E. Shaw & Co., Inc. | 3.37M | ▲ 974.85K |
| Cormorant Asset Management, LP | 3.21M | ▼ 1.27M |
| Logos Global Management LP | 2.67M | ▲ 1.18M |
| Weiss Asset Management LP | 2.58M | ▲ 873.49K |
| Citadel Advisors LLC | 1.97M | ▲ 649.16K |
| Two Sigma Investments, LP | 1.72M | ▲ 593.04K |
| Bioimpact Capital LLC | 1.61M | ▼ 204.12K |
| Vivo Capital, LLC | 1.40M | ▲ 400.00K |
Held by 57 ETFs
Biggest fund positions in MLTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jul 27, 26 | Reich Kristian | sell | 1,100 |
| Jul 21, 26 | Reich Kristian | sell | 50,000 |
| Jul 22, 26 | Reich Kristian | sell | 2,448 |
| Jul 20, 26 | Reich Kristian | sell | 43,700 |
| Jul 15, 26 | Reich Kristian | sell | 16,105 |
| Jul 9, 26 | Santos da Silva Jorge | sell | 33,936 |
| Jul 10, 26 | Santos da Silva Jorge | sell | 68,289 |
| Jul 1, 26 | Santos da Silva Jorge | sell | 47,775 |
| Jun 22, 26 | Bodenstedt Matthias | sell | 39,120 |
| Jun 17, 26 | BVF PARTNERS L P/IL | other | 22,195 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our MLTX coverage
Recent articles, reports, and earnings notes.
No research on MLTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MLTX report →MoonLake Immunotherapeutics Target of Unusually High Options Trading (NASDAQ:MLTX)
defenseworld.net · Aug 11
MoonLake's psoriatic arthritis drug meets key goals in late-stage trial
reuters.com · Aug 10
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
globenewswire.com · Aug 10
Arrowstreet Capital Limited Partnership Acquires New Shares in MoonLake Immunotherapeutics $MLTX
defenseworld.net · Aug 6
Wall Street Analysts See a 73.35% Upside in MOONLAKE IMMUNO (MLTX): Can the Stock Really Move This High?
zacks.com · Jul 31
MoonLake Immunotherapeutics' CFO Sells 39K Shares
fool.com · Jul 3
MoonLake: 'Buy' Sonelokimab BLA Submission HS September And Label Expansion
seekingalpha.com · Jun 26
Why MoonLake Immunotherapeutics Stock Wilted on Wednesday
fool.com · Jun 24
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.